INS and myeloproliferative disorder: Compared with insulin, GLP-1RA use was associated with a significantly lower risk of myeloid leukemia (HR, 0.39; 95% CI, 0.25-0.60), lymphoid leukemia (HR, 0.45; 95% CI, 0.30-0.68), non-Hodgkin lymphoma (HR, 0.42; 95% CI, 0.30-0.58), MDS (HR, 0.19; 95% CI, 0.11-0.35), MPN (HR, 0.50; 95% CI, 0.41-0.61), monoclonal gammopathy (HR, 0.68; 95% CI, 0.52-0.88), multiple myeloma (HR, 0.49; 95% CI, 0.31-0.76), and amyloidosis (HR, 0.52; 95% CI, 0.27-0.98).